Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

25%

3 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

7(63.6%)

Phase 3

3(27.3%)

Phase 1

1(9.1%)

11Total

Phase 2(7)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT05190991Phase 2Recruiting

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Role: collaborator

NCT05092776Phase 2Active Not Recruiting

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Role: collaborator

NCT06440746Phase 2Recruiting

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Role: collaborator

NCT05673902Phase 3Active Not Recruiting

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Role: collaborator

NCT05432960Phase 3Withdrawn

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Role: collaborator

NCT05107934Phase 2Suspended

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

Role: collaborator

NCT04463251Phase 2Completed

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Role: collaborator

NCT06320353Phase 3Active Not Recruiting

Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

Role: collaborator

NCT06307093Phase 1Active Not Recruiting

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Role: collaborator

NCT05196477Completed

Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

Role: collaborator

NCT04692766Phase 2Completed

Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

Role: collaborator

NCT04380519Phase 2Completed

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Role: collaborator

All 12 trials loaded